JupiteX Get the app
Health & Medicine17 Nov 2026 · about 7 min

Eritrea: Eritrea Eliminates Trachoma - a Major Public Health Milestone

The brief

WHO validation is an independent confirmation that a country has met agreed epidemiological thresholds for eliminating trachoma as a public health problem. WHO makes this decision after an independent, WHO-appointed review group examines the evidence submitted by the country. The review also confirms that systems exist to detect and manage future cases. That is the milestone Eritrea reached after two decades of effort. It means the disease no longer meets the threshold for being a public health problem in the country; it does not mean trachoma has disappeared everywhere. Eritrea has also established systems to identify and manage new cases of trichiasis. Eradication is a different, global idea: it means ending the disease everywhere, not just reaching a country-level threshold. Trachoma remains a public health problem in at least part of 29 countries, and 92 million people lived in endemic areas as of March 2026. Continued surveillance will help Eritrea protect its gains.

01

What does WHO mean when it validates a country’s elimination of trachoma as a public health problem, and how is that different from eradicating the disease everywhere?

WHO validation is an independent confirmation that a country has met agreed epidemiological thresholds for eliminating trachoma as a public health problem. WHO makes this decision after an independent, WHO-appointed review group examines the evidence submitted by the country. The review also confirms that systems exist to detect and manage future cases.

That is the milestone Eritrea reached after two decades of effort. It means the disease no longer meets the threshold for being a public health problem in the country; it does not mean trachoma has disappeared everywhere. Eritrea has also established systems to identify and manage new cases of trichiasis.

Eradication is a different, global idea: it means ending the disease everywhere, not just reaching a country-level threshold. Trachoma remains a public health problem in at least part of 29 countries, and 92 million people lived in endemic areas as of March 2026. Continued surveillance will help Eritrea protect its gains.

02

How many countries have reached this milestone, and how many people still live in areas where trachoma is a risk?

Eritrea’s validation brings the total to 34 countries worldwide that have eliminated trachoma as a public health problem. It is the 11th country in WHO’s African Region to reach this milestone. These figures mark progress against a disease that can cause blindness and is closely linked to poverty and gaps in basic services.

The remaining risk is substantial. As of March 2026, 92 million people lived in areas where trachoma was endemic and were at risk of trachoma blindness. The disease remained a public health problem in at least part of 29 countries. In 2025, 98 829 people received surgery for advanced disease, while 47.4 million received antibiotics.

The global population requiring interventions has fallen sharply, from an estimated 1.5 billion in 2002 to below 100 million by November 2025, a reduction of about 94%. Eritrea’s continued surveillance and case management will help sustain its gains, while other affected countries work toward elimination.

03

What will Eritrea keep doing after validation to find and manage new cases and protect the gains it has made?

Validation does not end Eritrea’s work. The country has established systems to identify and manage new cases of trichiasis, the advanced condition in which eyelashes turn inward. It will also continue surveillance after WHO’s validation. These steps are part of protecting the gains made through years of prevention and treatment.

Eritrea used surveys to identify where trachoma was present, then expanded interventions wherever it was endemic. Health workers used digital tools to collect data and map affected communities, including hard-to-reach areas. WHO’s validation process also checks that a country has systems to detect and manage future cases, not only evidence that it met the required thresholds.

The article does not specify how often surveillance will take place or which tools will be used next. It does state that Eritrea will continue monitoring and case management. This ongoing work is important because trachoma still affects communities in many countries, and 92 million people lived in endemic areas as of March 2026.

04

How does the SAFE strategy tackle trachoma through surgery, antibiotics, facial cleanliness, and environmental improvements?

WHO’s SAFE strategy tackles trachoma in four connected ways. Surgery treats trachomatous trichiasis, the advanced stage in which eyelashes turn inward. Antibiotics clear infection. Facial cleanliness helps reduce transmission, while environmental improvements focus particularly on better access to water and sanitation. Together, these measures address both illness and conditions that help it spread.

Eritrea first conducted baseline surveys in different parts of the country between 2006 and 2020. It then progressively used SAFE in communities where interventions were needed. The country surveyed all 58 sub-zobas and expanded work wherever trachoma was endemic. Oral azithromycin was the main antibiotic distributed, donated by Pfizer through the International Trachoma Initiative.

This combination helped Eritrea address a disease that spreads through contact with eye and nasal discharge from infected people. It also responds to the limited access to health care, clean water, and sanitation experienced in many remote rural areas. Eritrea will continue surveillance and manage new trichiasis cases after validation, helping sustain its progress.

05

How did community-led sanitation and digital mapping help Eritrea reach remote communities and target its efforts?

Eritrea’s programme paired community leadership with practical tools to reach people who might otherwise be missed. A community-led sanitation approach helped achieve significant public health gains despite limited external funding. This mattered in a country where many people live in remote rural areas with limited access to health care, clean water, and sanitation.

Health workers used digital tools to collect data and map affected communities. The maps helped them identify where trachoma was present and target resources, including in hard-to-reach areas. Eritrea also surveyed all 58 sub-zobas, or second-level administrative areas, and scaled up interventions wherever the disease was endemic. Surveys helped guide where the SAFE strategy was needed.

The approach combined community action, national leadership, health workers, and partners. Eritrea has now been validated by WHO, but it will continue surveillance and manage new trichiasis cases. The article gives no specific figures for how many people the mapping reached; it describes the tools as a way to focus efforts where they were needed.

06

What is trachoma, and how can repeated infections eventually cause blindness?

Trachoma is an eye disease caused by the bacterium Chlamydia trachomatis. It spreads through contact with eye and nasal discharge from infected people. The disease is closely associated with poverty and unequal access to basic services, including water, sanitation, hygiene, and health care. It is the world’s leading infectious cause of blindness.

The danger can build over time. Repeated infections may scar the inside of the eyelid. That scarring can make the eyelashes turn inward, a condition called trichiasis. The lashes then rub against the eye, and the disease can ultimately result in blindness. Surgery for trachomatous trichiasis is one part of WHO’s SAFE strategy.

Trachoma remains a risk for millions of people. As of March 2026, 92 million people lived in endemic areas and were at risk of trachoma blindness. Eritrea has systems to identify and manage new trichiasis cases and will continue surveillance after validation. These steps help protect the country’s progress while the disease remains a public health problem in parts of other countries.

07

Why do limited access to clean water, sanitation, and health care make infectious diseases like trachoma harder to prevent?

Trachoma is closely associated with poverty and inequities in access to basic services. The disease spreads through contact with eye and nasal discharge from infected people, and the article notes that limited access to clean water and sanitation can create conditions that facilitate transmission. These challenges are common in remote rural areas, where health care may also be difficult to reach.

Eritrea’s experience illustrates the link. Many people live in remote rural communities with limited access to health care, clean water, and sanitation. The country used WHO’s SAFE strategy: antibiotics to clear infection, facial cleanliness to reduce transmission, surgery for trichiasis, and environmental improvements, particularly better water and sanitation. Community-led sanitation also helped deliver public health gains.

These needs persist beyond one country. As of March 2026, 92 million people lived in trachoma-endemic areas, and the disease remained a public health problem in at least part of 29 countries. Improving access to essential services and continuing surveillance are important parts of protecting progress and reducing future risk.

This brief was written by AI from the original reporting and checked by other models. Names, figures and quotes come from the source; read it for full context.

Read more in the JupiteX app

Pulse is free. New stories every 4 hours, each one broken into the questions that explain it.

Or read more news on the web